Objective:
The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg /
day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as
control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with
atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2) who are undergoing PCI-S.
Design:
Randomized, parallel, with two arms, blind evaluation by third parties.
Patients:
304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ≤
2), which requires prevention of thrombosis
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute